PYX Resources: Achieving volume and diversification milestones. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
That's another woeful decision from AVCT's board IMO. AS was a key part of the story here, having been involved since before the 2006 IPO. To get the company to this stage and then be booted is extremely strange.
Bye Oxygen can you take Wynbag with you
Disappointed AS has been ousted, CC turns the language down and DX to go. Just hope CC ‘s business skills match her scientific ones. Meanwhile the CFO and Chairman ( don’t worry about funding ) escape….hmm, not impressed. Shall now review my investment here.
As I said…
Why do you care ?
Perhaps he’s repulsed by the unpleasant and disgraceful behaviour of a vocal element of self-appointed IR representatives in the company’s shareholder base, as exhibited on this forum every day. I am.
That very thought crossed my mind too Starbright, and the exciting thing for us LTHs is for AS to do that he would almost certainly want to time his exit to coincide with a sale, merger, NASDAQ listing?. Hence enabling him to take some cash off the table for his retirement.
This announcement today is another clue of where this company is headed. Some people can see it others are oblivious. don’t really care what happens short term to the share price on AIM. 😊 10% COS on broker note 🤣🤣🤣🤣 still find that highly amusing.
Chris would make an excellent future CEO
Perhaps AS - who doesn’t appear to enjoy the grim reality of being a CEO rather than a scientist - is setting up a lucrative exit (deservedly so, imo) following a paradigm changing commercial announcement/development, and Dr. Coughlin is to be his successor..?
Christina has. Joined us because our platform doesn’t work 😊
CC going to be busy what about affimers perhaps still on the back burner , who is leading that research & dvelopment ?
Great to see AIM investors fully appreciating the significance of a senior industry consultant taking the somewhat unusual decision to relinquish her independence and go 'all in' as an employee with a virtually unknown, tiny biotech from Wetherby.
I wonder why she did that ??
When are we expecting completion of C7 and data/results to be announced?
Down side relating to her previous companies tech...'Despite impressive advances, there are multiple outstanding challenges with NK cell therapies. Methods following good manufacturing practices to generate large clinical doses from a single healthy donor and selective expansion appropriate NK cell subsets with best predictive KIR/HLA are needed. Additionally, tumor immune evasion remains a large barrier. Once the NK or CAR-NK cells are infused into the patient, the long-term persistence of these cells in-vivo in the tumor microenvironment needs to be ensured and monitored. Another limitation with NK and CAR-NK cells is the memory property in vivo, which is not fully understood as in the case of memory T cells in adaptive immunity. Identifying novel CAR targets and generation of NK specific CAR constructs will enable CAR-NK cell homing and persistence in solid tumors contributing to breakthrough approaches driving allogeneic NK therapies towards the next frontier of cancer immunotherapy.'
Timster...'She's not made that move into a company on the verge of failure.'...agree...
She's just left a CEO potion in small company in early stage trials...why make the move to Avacta. Is it purely based on a move back to UK or is Avacta trial data far more attractive than that of the company she just left. We've announced her appoingment but her last company doesn't appear to have announced her leaving...
I've mention the above because this apppointment might be much bigger than we think if she believes the PreCision will be better for patient treatment/outcomes than what she's just been involved in...mmmm!!!
Timster absolutely, it’s all about winning awards now and changing the world. Avacta trusted her with the strategy of making the FDA and the USA lead AVA6000 (pivotal to AVA6000 strategy in RNS), now the results are out they can confidently say the below.
“next frontier in oncology innovation” that’s big words for a company that doesn’t boost things.
Cohort 7 results are going to change everything in Oncology innovation imo.
Very exciting times. 😊
Spot on ice, gone from consultant on great money but with none of the trappings of permanent employment.
Sure she's being paid well, but now has share options, pension, holiday, etc etc
She's not made that move into a company on the verge of failure.
This is absolutely brilliant news. Will have many contacts in the USA and taking a staff position after being a consultant for many years means this is more than money.
"a pivotal time for the company as we move our game-changing pipeline forward"
She knows funding is taken care of and she can focus not just on AVA6000 BUT 3996 and the rest of the pipeline.
When appointed as a consultant on 20th September Dr Christina Coughlin, commented:
"The potential of the pre|CISIONTM platform to deliver significant improvement to cancer patient outcomes is very exciting. The team, led by Neil, has done an excellent job and I am delighted to have the opportunity to work with them to complete the hugely successful dose escalation study and move into the dose expansion study in soft tissue sarcoma patients later this year.
"Beyond that we have potential to exploit AVA6000 to treat other cancers such as breast and ovarian and a wealth of opportunities to build our pipeline and partnerships. I am looking forward to working with the team on this strategy at this very exciting time."
She might well know something good is coming
She knows something.
I consider this appt and Christina's statements within the rns very significant. I hope and expect this will mean we will not see the share price as low as this again..
"Game changing pipeline " that will do for me.